Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 219

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 219
---
----|:--------------|------------:|:--|:----|:-----------|-----------:|:--|
| Research and development       |     | $             |  5,288,580 |   |     | $             |   9,845,603 |   |     | $          | (4,557,023 | ) |
| General and administrative     |     |               |  2,386,469 |   |     |               |   2,125,628 |   |     |            |    260,841 |   |
| Total operating expenses       |     |               |  7,675,049 |   |     |               |  11,971,231 |   |     |            | (4,296,182 | ) |
| Loss from operations           |     |               | (7,675,049 | ) |     |               | (11,971,231 | ) |     |            |  4,296,182 |   |
| Interest and other income, net |     |               |    385,472 |   |     |               |     142,115 |   |     |            |    243,357 |   |
| Net loss                       |     | $             | (7,289,577 | ) |     | $             | (11,829,116 | ) |     | $          |  4,539,539 |   |

General and Administrative Expenses General and administrative expenses were $2.39 million for the year ended December 31, 2023 compared to $2.13 million for the year ended December 31, 2022, reflecting a decrease of $0.26 million. Compensation related expenses decreased $0.87 million in 2023 as compared to 2022, due primarily to reduced headcount and recruiting expenses and reduction in software and other employee support expenses contributed $0.15 million to the 2023 decrease from 2022. Intellectual property expenses declined $0.07 million and public communication services expenses declined $0.04 million in 2023 relative to 2022. These decreases in expenses were offset by a $1.41 million increase in legal, accounting, and business consulting fees related to outsourced finance functions and activity related to preparation for the Business Combination. Research and Development Expenses R&D expenses were $5.29 million for the year ended December 31, 2023, compared to $9.